Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Torsten Böhmer

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Current Opinion in Molecular Therapeutics|October 27, 2005
Technology evaluation: Onyvax-P, OnyvaxChristian Doehn, Torsten Böhmer, Dieter Jocham
Current Opinion in Molecular Therapeutics|April 27, 2007
Drug evaluation: Therion's rV-PSA-TRICOM + rF-PSA-TRICOM prime-boost prostate cancer vaccineChristian Doehn, Ingo Kausch, Torsten Böhmer, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 19, 2008
Prostate cancer vaccines: current status and future potentialChristian Doehn, Torsten Böhmer, Ingo Kausch, et al.
International Journal of Oncology|October 9, 2002
Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcomeStefan Krüger, Georg Weitsch, Hartwig Büttner, et al.
International Journal of Cancer|November 15, 2002
HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implicationsStefan Krüger, Georg Weitsch, Hartwig Büttner, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Current Opinion in Molecular Therapeutics|October 27, 2005
Technology evaluation: Onyvax-P, OnyvaxChristian Doehn, Torsten Böhmer, Dieter Jocham
Current Opinion in Molecular Therapeutics|April 27, 2007
Drug evaluation: Therion's rV-PSA-TRICOM + rF-PSA-TRICOM prime-boost prostate cancer vaccineChristian Doehn, Ingo Kausch, Torsten Böhmer, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 19, 2008
Prostate cancer vaccines: current status and future potentialChristian Doehn, Torsten Böhmer, Ingo Kausch, et al.
International Journal of Oncology|October 9, 2002
Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcomeStefan Krüger, Georg Weitsch, Hartwig Büttner, et al.
International Journal of Cancer|November 15, 2002
HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implicationsStefan Krüger, Georg Weitsch, Hartwig Büttner, et al.
Pageof 1